Close Menu

IPO

NEW YORK (GenomeWeb News) – Biocept today set the price range on its planned initial public offering, saying it expects to price its shares between $10 and $12.

NEW YORK (GenomeWeb News) – Veracyte announced after the close of the market Monday that it has completed its initial public offering.
The firm went public last week offering 5 million shares at $13 per share. The IPO brought in net proceeds of $58 million.

NEW YORK (GenomeWeb News) – CardioDx today set the price range on its planned initial public offering and raised the maximum proposed aggregate offering price to $92.0 million.

NEW YORK (GenomeWeb News) – Molecular diagnostics firm AutoGenomics filed with the US Securities and Exchange Commission to officially withdraw a planned initial public offering.

NEW YORK (GenomeWeb News) – Veracyte today priced its initial public offering of 5 million shares at $13 per share.

NEW YORK (GenomeWeb News) – Cardiovascular molecular diagnostics firm CardioDx, which plans to go public with an intended offering of up to $86.3 million, said that its revenues for the first

NEW YORK (GenomeWeb News) – Veracyte today increased the proposed maximum aggregate offering amount for its planned initial public offering to $81.1 million.

NEW YORK (GenomeWeb News) – Cardiovascular molecular diagnostics firm CardioDx has filed with the US Securities and Exchange Commission to go public with an intended offering of up to $86.3 million of common stock.

NEW YORK (GenomeWeb News) – Shares of Foundation Medicine soared in their debut on the Nasdaq Global Select Market this morning.

NEW YORK (GenomeWeb News) – Circulating tumor cell-based diagnostics firm Biocept on Monday filed with US regulators to go public with an initial public offering intended to raise up to $24.25 million.

Pages

According to ScienceInsider, the US National Academies of Science, Engineering, and Medicine is planning a study of racism in academic research.

The Washington Post writes that the approval in the US of a SARS-CoV-2 vaccine will be up to Peter Marks, a career official at the Food and Drug Administration.

NPR reports the US loan to Eastman Kodak to boost domestic pharmaceutical production is on pause following insider trading allegations.

In Cell this week: blood immune cell changes in COVID-19 patients and spatial transcriptomics in Alzheimer's disease.